Moreover, BRAF mutation is regarded as a target for tyrosine kinase inhibitor intervention in signal transduction pathway therapy, with which significant progress has been made in the treatment of malignant melanoma.[23] Therefore, the 2019 Chinese society of clinical oncology Melanoma Diagnosis and Treatment Guidelines recommend the routine detection of BRAF mutations in malignant melanoma patients, improving the significance of subsequent treatment decisions. Here, BRAF is linked to melanoma.